Comparative Pharmacology
Head-to-head clinical analysis: ADHANSIA XR versus DEXEDRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADHANSIA XR versus DEXEDRINE.
ADHANSIA XR vs DEXEDRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
None Documented
None Documented
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Category C
Category C
CNS Stimulant
CNS Stimulant